• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Gene Signatures and Oncology Treatment Implications.基因特征与肿瘤治疗意义
Hematol Oncol Clin North Am. 2025 Apr;39(2):295-307. doi: 10.1016/j.hoc.2024.11.003. Epub 2024 Dec 17.
2
Synthetic lethality-mediated precision oncology via the tumor transcriptome.基于肿瘤转录组的合成致死性介导精准肿瘤学。
Cell. 2021 Apr 29;184(9):2487-2502.e13. doi: 10.1016/j.cell.2021.03.030. Epub 2021 Apr 14.
3
Gene-expression profiling to predict responsiveness to immunotherapy.基因表达谱分析预测免疫治疗反应性。
Cancer Gene Ther. 2017 Mar;24(3):134-140. doi: 10.1038/cgt.2016.63. Epub 2016 Nov 11.
4
Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study.在3P医学背景下基于十二种程序性细胞死亡模式的浆液性卵巢癌新型标志物的多组学鉴定:一项多队列机器学习研究
Mol Med. 2025 Jan 8;31(1):5. doi: 10.1186/s10020-024-01036-x.
5
A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.一种新的思路:扩展基因组选择的应用,筛选多组学数据,以开发新型缺氧免疫生物标志物,并为透明细胞肾细胞癌的靶向治疗提供新的靶点。
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab173.
6
Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine.转录组学在个性化癌症医学中的当前成就和应用。
Int J Mol Sci. 2021 Jan 31;22(3):1422. doi: 10.3390/ijms22031422.
7
Transcriptomics and solid tumors: The next frontier in precision cancer medicine.转录组学与实体肿瘤:精准肿瘤医学的下一个前沿领域。
Semin Cancer Biol. 2022 Sep;84:50-59. doi: 10.1016/j.semcancer.2020.09.007. Epub 2020 Sep 17.
8
Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.基于转录组的微环境分类揭示了胰腺导管腺癌的精准医疗策略。
Gastroenterology. 2024 May;166(5):859-871.e3. doi: 10.1053/j.gastro.2024.01.028. Epub 2024 Jan 25.
9
Comprehensive single-cell and bulk transcriptomic analyses to develop an NK cell-derived gene signature for prognostic assessment and precision medicine in breast cancer.全面的单细胞和批量转录组分析,为乳腺癌的预后评估和精准医学开发 NK 细胞衍生的基因特征。
Front Immunol. 2024 Oct 23;15:1460607. doi: 10.3389/fimmu.2024.1460607. eCollection 2024.
10
A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence.基于血管内皮衰老的转录组 pan 癌特征用于生存预后预测和免疫治疗反应预测。
J Biomed Sci. 2023 Mar 28;30(1):21. doi: 10.1186/s12929-023-00915-5.

本文引用的文献

1
The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT PREDICT Study.7基因生物标志物在保乳手术后导管原位癌患者放疗决策中的临床应用:DCISionRT PREDICT研究的最新分析
Ann Surg Oncol. 2024 Sep;31(9):5919-5928. doi: 10.1245/s10434-024-15566-5. Epub 2024 Jun 25.
2
Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature.利用趋同表型推导泛癌顺铂反应基因表达特征。
NPJ Precis Oncol. 2023 Apr 19;7(1):38. doi: 10.1038/s41698-023-00375-y.
3
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.修订版国际分期系统(R2-ISS)在多发性骨髓瘤整体生存中的应用:Harmony 项目下欧洲骨髓瘤网络(EMN)的报告。
J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.
4
Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology.精准医学研究向放射肿瘤学中基于生物标志物的护理的转化。
Semin Radiat Oncol. 2022 Jan;32(1):42-53. doi: 10.1016/j.semradonc.2021.09.001.
5
Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma.网络潜力可鉴定尤文肉瘤治疗性 miRNA 鸡尾酒。
PLoS Comput Biol. 2021 Oct 18;17(10):e1008755. doi: 10.1371/journal.pcbi.1008755. eCollection 2021 Oct.
6
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.临床细胞周期风险(CCR)评分与放疗后的转移相关,并为何时放弃联合雄激素剥夺治疗与剂量递增放疗提供指导。
Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):66-76. doi: 10.1016/j.ijrobp.2021.09.034. Epub 2021 Oct 3.
7
Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.验证细胞周期进展评分在经尿道前列腺切除术活检诊断的男性中区分惰性与侵袭性前列腺癌的能力。
Cancer Rep (Hoboken). 2022 Aug;5(8):e1535. doi: 10.1002/cnr2.1535. Epub 2021 Aug 22.
8
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.利用基因组调整后的放射剂量(GARD)进行泛癌放疗获益预测:基于队列的汇总分析。
Lancet Oncol. 2021 Sep;22(9):1221-1229. doi: 10.1016/S1470-2045(21)00347-8. Epub 2021 Aug 4.
9
GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality.GPS 检测与长期癌症结果的相关性:20 年远处转移风险和前列腺癌特异性死亡率。
JCO Precis Oncol. 2021 Feb 24;5. doi: 10.1200/PO.20.00325. eCollection 2021.
10
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.个体化局部前列腺癌:联合临床细胞周期风险(CCR)评分阈值预测多模态治疗获益的验证。
Clin Genitourin Cancer. 2021 Aug;19(4):296-304.e3. doi: 10.1016/j.clgc.2021.01.003. Epub 2021 Jan 19.

基因特征与肿瘤治疗意义

Gene Signatures and Oncology Treatment Implications.

作者信息

Scarborough Jessica, Weaver Davis, Scott Jacob

机构信息

Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA.

Department of Translational Hematology and Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA; Systems Biology and Bioinformatics, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.

出版信息

Hematol Oncol Clin North Am. 2025 Apr;39(2):295-307. doi: 10.1016/j.hoc.2024.11.003. Epub 2024 Dec 17.

DOI:10.1016/j.hoc.2024.11.003
PMID:39694780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11867875/
Abstract

Gene expression signatures (GES) are a powerful tool in oncology used for classification, prognostication, and therapeutic response prediction of malignancies. In this article, we review the disease site guidelines by the National Comprehensive Cancer Network that use GES for treatment planning and clinical use. We identified 4 cancer types for which treatment decisions are frequently influenced by GES. Future developments in the field of GES are likely to include expanded data sources to personalize radiation therapy dosing and predict response to immunotherapy. Ongoing challenges in GES may be addressed to ensure that all patients with cancer benefit from precision oncology.

摘要

基因表达特征(GES)是肿瘤学中用于恶性肿瘤分类、预后评估和治疗反应预测的强大工具。在本文中,我们回顾了美国国立综合癌症网络的疾病部位指南,该指南将GES用于治疗规划和临床应用。我们确定了4种癌症类型,其治疗决策经常受到GES的影响。GES领域未来的发展可能包括扩大数据源,以实现放射治疗剂量的个性化并预测对免疫治疗的反应。GES中持续存在的挑战可能会得到解决,以确保所有癌症患者都能从精准肿瘤学中受益。